Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons N.M.A. Idzerda

Publicaties

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores

An acute rise of plasma Na+ concentration associates with syndecan-1 shedding during hemodialysis

Better prediction of drug response in diabetic kidney disease: a biomarker approach to personalize therapy

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

Future and Novel Compounds in the Treatment of Diabetic Nephropathy

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Plasma syndecan-1 in hemodialysis patients associates with survival and lower markers of volume status

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; apost hoc analysis of the PLANET trials

Lees meer